CCORF Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $14
Rezolute Analyst Ratings
BTIG Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $15
Analysts' Opinions Are Mixed on These Healthcare Stocks: Rezolute (RZLT) and Gryphon Digital Mining (GRYP)
JMP Securities Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for Rezolute Amidst Progressive Clinical Trials and Strong Financial Position
Rezolute Is Maintained at Buy by BTIG
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating
Rezolute's Drug Pipeline Progress and FDA Hold Lift Propel Buy Rating and Increased Price Target
A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $7 to $15
Rezolute Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $14 Price Target
Rezolute Buy Rating Affirmed: RZ358 Clinical Advancements and Strong Market Potential
Guggenheim Initiates Rezolute(RZLT.US) With Buy Rating, Announces Target Price $11
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating
Rezolute Price Target Raised to $10.00/Share From $8.00 by Maxim Group
Craig-Hallum Maintains Rezolute(RZLT.US) With Buy Rating, Announces Target Price $13
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Adaptive Biotechnologies (ADPT) and Rezolute (RZLT)
Craig-Hallum Sticks to Its Buy Rating for Rezolute (RZLT)